A Study Shows Treatment Combining Lower Doses of Chemotherapy with INO Is Safe and Effective
A research led by The University of Texas MD Anderson Cancer Center confirmed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is protected and efficient in patients over 60 years of age who had been newly recognized with a high-risk type of acute lymphoblastic leukemia (ALL) often called Philadelphia chromosome-negative ALL.
Findings from the examine had been presented by Nicholas Short, M.D., assistant professor of Leukemia, Dec. 9 on the 61st American Society of Hematology Annual Meeting & Exposition in Orlando, Fla. The examine was led by Elias Jabbour, M.D., professor of Leukemia.
Previous international research, each led by MD Anderson investigators, confirmed that blinatumomab and INO given as single brokers have been more practical than standard chemotherapy for treatment of advanced ALL, and are actually being added as frontline treatment options.
The examine handled 64 patients with a median age of 68 years. Among the many 59 evaluable sufferers, 58 or 98% of them achieved a whole response. With a median comply with-up of 37 months, the three-year general survival rate was 54%, with 30 patients in complete remission with no signs of minimal residual disease.
The outcomes of patients who did or didn’t obtained blinatumomab have been related, though, will want more follow-up to determine whether or not the addition of blinatumomab will improve outcomes within the long-term. This trial resulted in considerably higher three-year survival rates in comparison with the 32% survival charges noticed in the same historical cohort of older patients treated with intensive chemotherapy. These findings might represent a brand new standard of care for this older population.